Drugs that inhibit the liver enzyme CYP2D6 might theoretically increase<unk>  concentrations in the body, as the latter is metabolized by this enzyme; but this has been found to be of no clinical significance. While the drug itself is a moderate CYP2D6 inhibitor, it is not expected to have a relevant impact on other pharmaceuticals that are broken down by this enzyme, because it only remains in the body for a short time.<unk>  probably interacts with other antiarrhythmic drugs, although no formal studies have been done.
Vernakalant
Bocasan
Atogepant
Tasimelteon
Seltorexant
Pulmocide
Veristrat
Bretylium